Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Panthenol

Also known as: provitamin B5, D-panthenol, dexpanthenol

Panthenol is an alcohol analogue of vitamin B5 used as a humectant in skin and hair products. Dexpanthenol is its D-form. Panthenol-containing moisturisers and some wound-care preparations have been studied for hydration, irritant response and recovery of superficially injured skin.

In plain English — Panthenol is a moisturising ingredient related to vitamin B5. Some products containing its D-form, dexpanthenol, have helped skin retain moisture or supported early healing in clinical studies. The finished product and the condition being treated matter when applying those findings.

Evidence status

Moderate

Established humectant; formulation-specific clinical evidence. Human controlled studies support hydration and some early wound-healing outcomes for particular dexpanthenol preparations. Evidence spans experimental irritation, clinical procedures and laboratory models; applicability depends on the formulation, setting and outcome.

What panthenol is, and the types available#

Panthenol is related to pantothenic acid, or vitamin B5, and is used to help retain water in cosmetic formulations and skin. Dexpanthenol denotes D-panthenol; cosmetic ingredient names can also encompass a mixture of D- and L-forms. The ingredient occurs in skin and hair products, including leave-on moisturisers.[1]

Creams, lotions and ointments provide different ways of delivering dexpanthenol. Some preparations are intended for routine moisturising, while others have been developed and studied for superficial wound care.[1, 4] The subject here is topical ingredient and formulation evidence. Skin barrier explains protective function; stratum corneum explains the anatomy.

Use of panthenol in aesthetic practice#

Panthenol’s principal relevance is supportive skin care: hydration and the selection of a comfortable moisturising preparation. It can sit within an emollient formula alongside other water-binding ingredients and a lipid-containing vehicle. The intended outcome should be clear — less dryness, improved comfort or a particular documented recovery endpoint.[1, 4][2][7]

Post-procedure care is a separate use setting. A dexpanthenol ointment has been studied after fractional ablative laser, but choosing care for an actual procedural wound belongs to the treating clinician and the relevant product and treatment instructions. The presence of panthenol in a cosmetic serum is insufficient to establish that use.[1, 3, 6]i

Contraindications and cautions#

A known allergy to panthenol, or to another constituent of the proposed preparation, makes avoidance important. Previous reactions to a wound cream or moisturiser should be recorded by product name rather than assumed to concern only its advertised active. In the Portuguese patch-test series discussed below, almost all dexpanthenol-reactive patients also reacted to other allergens.[4][8]

Inflamed, persistently stinging or weeping skin needs assessment appropriate to its presentation. Ointment selection is particularly relevant: NHS emollient advice distinguishes very dry skin, where a greasy preparation may be useful, from weeping eczema, where ointments are unsuitable.[7]Infant, pregnancy, mucosal and wound uses should be checked against the specific preparation’s instructions rather than inferred from a vitamin association.

Clinical uses and the evidence behind them#

Hydration during experimental irritation

Biro and colleagues enrolled 25 healthy adults aged 18–45 in a randomised, blinded, within-person study; 21 completed it. The inner forearms received a hand balm containing 5% dexpanthenol or placebo over 26 days, with sodium lauryl sulphate irritation during the study. Hydration assessed by corneometry was better preserved at active-treated sites. This was the only measured endpoint with a statistically significant treatment difference. The authors concluded that the preparation protected against irritation in this experimental setting.[2]

This is relevant human evidence for moisturising support under a controlled irritant challenge. Its setting was healthy forearm skin; application to facial symptoms or established dermatitis requires separate clinical judgement. The named product was Bepanthol Handbalsam; the retrieved abstract did not disclose sponsorship.[2, 3]i

Recovery after a clinical procedure

Heise and colleagues studied 38 patients after fractional ablative CO2 laser treatment of photodamaged skin. Each treated wound area was divided between dexpanthenol-containing ointment and petroleum jelly. Care lasted seven days, with follow-up to day 14. Early lesion closure favoured the dexpanthenol preparation; re-epithelialisation and appearance assessments also favoured it at early visits. All patients had completed healing by day 14. The available primary abstract does not identify the anatomical site.[3]

The original trial’s funding statement was unavailable. A subsequent review disclosed Bayer relationships for coauthor Baron and included Bayer employees and Bayer-funded writing assistance. These disclosures are relevant context, while the trial’s own sponsorship remains unconfirmed.[1, 2, 3, 6]i

Cosmetic safety

The Cosmetic Ingredient Review panel concluded that panthenol and its assessed relatives were safe within the cosmetic uses and concentrations it evaluated. This was a safety assessment, sponsored by CIR with funding from the Personal Care Products Council.[1] Individual tolerability remains part of product selection.

Selecting a panthenol-containing preparation#

Selection starts with the required role and the condition of the skin. For routine hydration, the vehicle’s texture, spreadability and tolerance are practical considerations: creams and ointments have different sensory and occlusive characteristics.[7] For a recovery claim, the useful comparison is with the tested finished preparation and setting.[2, 3]i

An ingredient list can identify panthenol and other potential exposures. It should be considered alongside the intended site, manufacturer instructions and the client’s product history. Clinical study concentrations describe those experiments; they are not a starting-strength or escalation schedule.[2, 3]i

Adverse effects and their management#

Contact allergy is a recognised possibility. A retrospective review at a Portuguese university dermatology service documented clinically relevant reactions associated with wound creams, moisturisers, a topical medicine and a shampoo.[4]

New dermatitis following a product warrants withdrawal of the suspected exposure and assessment of the whole formula and exposure history. Persistent symptoms or an unclear culprit can require dermatologist-led investigation.[8] Emollients can also cause persistent burning, follicular inflammation or facial eruptions; those reactions do not establish panthenol as the responsible ingredient.[7]

Residue from emollient products on clothing or bedding is a fire hazard. NHS advice includes paraffin-free products in the precaution to keep treated fabrics away from smoking, flames and other ignition sources. This is a preparation-and-fabric issue rather than a panthenol-specific toxic effect.[7]

Referral and scope boundaries#

Persistent, recurrent or severe dermatitis warrants medical assessment, with specialist referral when the cause remains uncertain or treatment is unsuccessful.[8] A practitioner can document product exposure and changes in symptoms; the diagnosis of allergic contact dermatitis and selection of diagnostic patch testing belong with the relevant clinical service.[4]

For care following a procedure, the treating clinician’s instructions and the preparation’s intended use govern product choice. Ingredient evidence is supplied here, not a procedural aftercare protocol. The clinical differential for irritated skin is addressed in impaired skin barrier.

Mechanism of action#

Two related aspects explain panthenol’s interest. Its water-binding properties support moisturisation. Dexpanthenol can also be converted to pantothenic acid, which contributes to coenzyme A biology. The latter supplies biochemical context rather than a measure of an individual product’s clinical effect. The review describing these mechanisms is manufacturer-authored and Bayer-funded.[6]

Experimental wound research adds more specific observations. Marquardt and colleagues used laser-injured, reconstructed three-dimensional human skin in vitro. Three dexpanthenol-containing emulsions enhanced closure compared with untreated models. Separate experiments added calcium pantothenate to culture medium and assessed gene expression. These were human-derived laboratory models, not treated patients, and the culture-medium intervention was distinct from the topical emulsions.[5]

Commonly misstated claims#

Vitamin-B5 ingredient identities

Claim heard:“Panthenol and every B5 derivative are interchangeable”

Literature finding: Panthenol, pantothenic acid, panthenyl esters and pantothenate salts are distinct chemical ingredients. A shared vitamin relationship does not identify an identical formulation or intervention.[1]

Supported statement: Name the ingredient and preparation actually studied.

Patch-test populations

Claim heard:“Panthenol causes allergy in 1.2% of users”

Literature finding: The denominator was 2,171 patients patch tested in a dermatology service, largely in the context of eczema among those reacting. The 26 positive tests generated the 1.2% figure; 20 of those reactions had identified clinical relevance. That selected diagnostic population cannot establish the incidence of new allergy among everyday users.[4]i

Supported statement:Dexpanthenol allergy is documented; this study’s frequency applies to its patch-tested population.

Early healing and later scarring

Claim heard:“Faster healing proves scar prevention”

Literature finding: The laser trial measured early closure, re-epithelialisation and appearance, with follow-up to day 14. Those endpoints support its early-recovery findings but do not measure long-term scar prevention.[3]i

Supported statement: Describe the observed early healing outcome without converting it into a long-term scarring claim.

Areas of remaining uncertainty#

  • Choice between moisturising preparations:direct comparisons across the products encountered in practice would better establish relative benefit. Selection therefore also weighs intended use, texture and the person’s tolerance.[2, 3]i[7]
  • Transfer between skin settings: healthy forearm irritation and recovery after laser are different populations and exposures. A proposed use in facial dryness or chronic inflammatory disease needs evidence applicable to that presentation.[2, 3]i
  • Patient-valued recovery: consistent measures of comfort and longer-term satisfaction would complement early closure measurements. Describe the outcome a study measured when discussing an expected benefit.[3]i

Frequently asked questions#

Is panthenol the same as dexpanthenol?

Dexpanthenol specifies the D-form of panthenol. The broader cosmetic ingredient name does not always specify stereochemistry.[1, 6]

How does it differ from ceramides?

Panthenol is used as a humectant.[1, 4] Ceramides covers the lipid family and the evidence for ceramide-containing formulations; a moisturiser can be assessed in terms of both its water-binding and lipid components.

Which page explains a barrier measurement in a product study?

TEWL explains transepidermal water loss and its interpretation. Corneometry, the significant endpoint in the Biro study, was a hydration measurement.[2]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Scott LN, Fiume M, Bergfeld WF, et al. Safety Assessment of Panthenol, Pantothenic Acid, and Derivatives as Used in Cosmetics. Int J Toxicol. 2022;41(3_suppl):77–128. doi:10.1177/10915818221124809. PMID:36177798.Tier 4Supports: Identity, cosmetic functions, stereochemistry, derivatives and cosmetic safety scope.Funding / interest: Sponsored by Cosmetic Ingredient Review, financially supported by the Personal Care Products Council. Authors declared no potential conflicts; the industry funding is disclosed separately. Full publisher text read.
  2. Biro K, Thaçi D, Ochsendorf FR, Kaufmann R, Boehncke WH. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49(2):80–84. doi:10.1111/j.0105-1873.2003.00184.x. PMID:14641355.Tier 2Supports: Healthy adult inner-forearm irritation experiment and its hydration endpoint.Funding / interest: Bepanthol Handbalsam was the named active product. Sponsor and conflict declarations were unavailable in the retrieved primary abstract; independence is not established.
  3. Heise R, Schmitt L, Huth L, et al. Accelerated wound healing with a dexpanthenol-containing ointment after fractional ablative CO2 laser resurfacing of photo-damaged skin in a randomized prospective clinical trial. Cutan Ocul Toxicol. 2019;38(3):274–278. doi:10.1080/15569527.2019.1597879. PMID:30897983.Tier 2Supports: Early closure and re-epithelialisation in a split-wound laser study.Funding / interest: Study funding and conflict statement unavailable in the primary abstract. Coauthor Baron disclosed Bayer honoraria and departmental Bayer research grants in source 6; this establishes a related commercial relationship, not the funding of this particular trial.
  4. Fernandes RA, Santiago L, Gouveia M, Gonçalo M. Allergic contact dermatitis caused by dexpanthenol—Probably a frequent allergen. Contact Dermatitis. 2018;79(5):276–280. doi:10.1111/cod.13054. PMID:30009460.Tier 3Supports: Relevant allergic reactions in a selected dermatology patch-test population.Funding / interest: Funding and conflict declarations unavailable in the retrieved primary abstract.
  5. Marquardt Y, Amann PM, Heise R, et al. Characterization of a novel standardized human three-dimensional skin wound healing model using non-sequential fractional ultrapulsed CO2 laser treatments. Lasers Surg Med. 2015;47(3):257–265. doi:10.1002/lsm.22341. PMID:25771913.In vitroTier 3Supports: Closure in reconstructed human skin and separate calcium-pantothenate culture experiments.Funding / interest: Named funding unavailable in the primary abstract. Coauthor Baron disclosed Bayer relationships in source 6; funding of this experiment remains unverified. Human-derived models are not patient trials.
  6. Gorski J, Proksch E, Baron JM, Schmid D, Zhang L. Dexpanthenol in Wound Healing after Medical and Cosmetic Interventions (Postprocedure Wound Healing). Pharmaceuticals (Basel). 2020;13(7):138. doi:10.3390/ph13070138. PMID:32610604.Tier 4Supports: Biochemical context, formulation types and disclosed relationships in the wound-care literature.Funding / interest: Manufacturer-authored. Gorski, Schmid and Zhang were Bayer employees; Proksch disclosed Bayer consulting honoraria and grants, and Baron Bayer honoraria and departmental grants. Bayer funded writing assistance. Search strategy stated, but treated as narrative synthesis, not a systematic efficacy review with formal bias assessment.
  7. NHS. Emollients. Public patient guidance. Accessed 16 September 2026.Tier 4Supports: Emollient vehicle selection, adverse reactions and fire precautions.Funding / interest: NHS public guidance; not an ingredient-sponsored clinical study.
  8. NHS. Contact dermatitis. Reviewed 3 May 2023. Accessed 16 September 2026.Tier 4Supports: Avoidance of causative substances and assessment of persistent, recurrent or severe symptoms.Funding / interest: NHS public guidance; not an ingredient-sponsored clinical study.